Cephalon, Inc.

Teva Biopharmaceuticals Usa, Inc.

Bridget Ann Cooksey

Anthony Gerard Doyle

Adam Clarke

Matthew Pollard

Lynn Dorothy Poulton

David Jose Simon Laine

Vanya Pande

Mark Terence Liddament

Julia Rozenfeld

Doris Shim Siew Chen

Jason William Gill

Anna Maria Matilda Quigley

Anna Mikaela Bracken

Marta Szabat

Craig A Rosen

Viktor Roschke

Rodger G Smith

Palanisamy Kanakaraj

Adam William Clarke

The present disclosure provides antibodies and antigen-binding fragments thereof that specifically bind to human PAR-2 and compositions comprising such antibodies or antigen-binding fragments thereof. In a particular aspect, the antibodies or antigen-binding fragments thereof that specifically bind to human PAR-2 block the interaction between a PAR-2 activating ligand and an extracellular domain of PAR-2, and/or blocks PAR-2 activation by a PAR-2 activating ligand, In further aspects, the antibodies or antigen-binding fragments can be used to treat diseases or conditions associated with increased expression of PAR-2 and/or diseases or conditions that can be alleviated by antagonizing activation of PAR-2 by a PAR-2 activating ligand (e.g., airway diseases, skin diseases, cancer, orofacial granulomatosis, inflammatory conditions, and pain associated with various diseases or conditions).

Anti-PAR-2 antibodies and methods of use thereof

Recombinantly expressed variant antibodies that have enhanced affinity for TL1A and enhanced potency relative to the parent antibody from which they were derived are provided. The antibodies inhibit the interaction between TL1A and the death receptor 3 (DR3). The antibodies, or a composition thereof, may be used to treat one or more of asthma, COPD, pulmonary fibrosis, cystic fibrosis, inflammatory bowel disease, a gastrointestinal disease associated with cystic fibrosis, Crohn's disease, colitis, ulcerative colitis, irritable bowel syndrome, eosinophilic esophagitis, atopic dermatitis, eczema, scleroderma, arthritis, or rheumatoid arthritis.

Antibodies that specifically bind to TL1A and methods of treating gastrointestinal disease

Disclosed herein are human antibody molecules that immunospecifically bind to human CXCR2. The disclosed human antibody molecules are potent and selective antagonists of CXCR2 functions and prevent the recruitment of neutrophils into tissues without strongly depleting circulating neutrophil numbers. Pharmaceutical compositions, nucleic acid molecules, vectors, cells, and uses of the disclosed antibodies are also provided.

Anti-CXCR2 antibodies and uses thereof

Antibodies that specifically bind to TL1A and methods of treating respiratory tract diseases

Disclosed herein are fully human antibody molecules that immunospecifically bind to human IL-5. The antibody molecules can bind to human IL-5 with an equilibrium affinity constant (K) of at least about 40 pM as determined by surface plasmon resonance.

Anti-IL-5 antibodies

Antibodies that specifically bind to TL1A

Disclosed are humanized antibodies that bind specifically to TNF superfamily member 15 (TNFSF15), also known as TL1A. Methods of making and using the anti-TL1A antibodies are also described. The humanized antibodies may be antagonists and may used to treat or diagnose conditions associated with TL1A function.

Humanized antibodies against TL1A

Growing community of inventors

Macquarie Park, Australia

Bridget Ann Cooksey